unknown
Stage
1
Investors
About
HanchorBio is an immune-oncology company that engineers Fc-Based Designer Biologics (FBDB™) to create ligand traps that block multi-ligand interactions involved in adaptive and innate immune activation. Its lead candidate HCB101 is a ligand trap targeting the SIPRα-CD47 signaling pathway and is in US Phase 1 clinical studies for advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.
Explore HanchorBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.